123ArticleOnline Logo
Welcome to 123ArticleOnline.com!

ALL >> Business >> View Article

Harver Group Targets Biotech Bull

By Author: Harver Group
Total Articles: 26

Jul. 24, 2013 - CHUO-KU, Japan -- Due to the huge increase in staff and board members buying stock in Synta Pharmaceuticals, and the successful trials of Synta Pharmaceuticals latest cancer drug Ganetespib, Pharmaceutical Analysts at Harver Group are now strongly recommending the stock as a buy to investors.

Stephen James, Director of Private Equity at Harver Group in Tokyo, commented “A huge indicator for me that a stock is about to take off is insider buying. We have seen quite a bit of this over the past few weeks at Synta Pharmaceuticals, Hedge Fund Manager, Bruce Kovner who has also been on the board of directors since 2002, has bought 3 million shares for just over $13 million. President and CEO Safi Bachall also bought 10,000 shares bring his total to almost 2 million.”

Synta Pharmaceuticals (SNTA) is a biopharmaceutical corporation which creates, develops, and commercializes drugs that extend and increase the standard of living of patients with cancer and other chronic diseases. The Company has a unique library of propriety chemical compounds acquired over two decades from academic and industrial sources. These compounds are optimized through a variety of techniques to create new drug candidates.

Their most exciting new drug candidate is called Ganetespib and is used to treat lung, breast, colorectal, and hemolytic cancer. Ganetespib is a small molecular inhibitor of heat shock protein 90 (Hsp90) which is required for the maturation and activation of a number of proteins. Cancer cells thrive in the presence of Hsp90, inhibiting it can greatly reduce tumors proliferation. The drug has been tested on over 700 patients in 20 clinical trials. Although trials are not finished and the company has not released a full report, the drug has shown a lot of promise.

Nathan Marx, Head of Investment Analysis said, “Although their share price has dropped from its $10 a share high in April, I expect it to return to this price in the next three months and I am recommending my clients to buy.” Peter Anderson, Senior Vice President of Mergers and Acquisitions at Harver Group said

“This is an exciting company, on the verge of a major breakthrough, displaying all the signs of a strong financial instrument for these coming quarters, so I’m confident our clients will see growth in this area”.

Total Views: 1270Word Count: 382See All articles From Author

Business Articles

1. How Ultratax In Cloud Offers Smart Taxation Solutions To Businesses?
Author: John Cox

2. Importance Of Electrical Surge Protection
Author: housedepotseo

3. Laparoscopic Gastric Bypass Part - Iii
Author: Unknown Member

4. Texas Property Tax Deadline Changes In 2018
Author: O'Connor & Associates

5. Take Your Business To New Heights
Author: sgartland

6. Physiotherapy Services In Mississauga
Author: gapconsultingcanada

7. Bariatric Coordinator
Author: Gastric bypass California

8. Get The Best Digital Marketing Solutions
Author: makemy website

9. 4 Of The Most Familiar Roofing Services In Nyc You May Need From Time To Time
Author: Gabriel M

10. Avail Reliable Customs Broker Us Border To Ensure Smooth And Efficient Transit Of Import Goods
Author: adkenkaylyn

11. The Indian Wedding – A Day Of Joy And Celebration Like No Other
Author: Shabu Miah

12. Business Card Design Services In Hyderabad – Saga Bizsolutions
Author: sagabizsolutions

13. Online Course In E-commerce And Selling Online
Author: nicole ve

14. Financial Strategies In Restaurant Business Plan
Author: royalcurryhousenarellan

15. Branded Watches For Men
Author: Innocententre

Login To Account
Login Email:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: